Portage Biotech confirms compliance with Nasdaq listing requirements, advancing its immuno-oncology pipeline.
Quiver AI Summary
Portage Biotech Inc. announced that it has received formal notice from The Nasdaq Stock Market confirming its compliance with the listing requirements for The Nasdaq Capital Market. This announcement was made on June 25, 2025, following the company's efforts in advancing a pipeline of novel biologics aimed at improving the immune system's capability to combat cancer. The press release includes forward-looking statements regarding the company's future operations and strategies, which are subject to various risks and uncertainties, such as financing challenges and potential scientific outcomes. The company emphasizes that actual results may differ significantly from those projected in these statements.
Potential Positives
- The company has demonstrated compliance with the Nasdaq listing requirements, which is essential for maintaining its market presence and investor confidence.
- This announcement can enhance investor confidence in Portage Biotech, signaling that the company is meeting regulatory and operational benchmarks necessary for its continued growth and stability.
- Being a clinical-stage immuno-oncology company, ongoing compliance with Nasdaq may attract more interest and investment, particularly as it advances its pipeline of novel biologics for cancer treatment.
- The news release positions Portage Biotech as a stable entity within the competitive biotech market, potentially aiding in strategic partnerships and collaborations due to its continued compliance status.
Potential Negatives
- The press release indicates the Company has narrowly complied with Nasdaq listing requirements, suggesting potential financial instability or operational challenges.
- There is an explicit mention of risks related to the company's ability to continue as a going concern, which raises concerns about its financial health.
- The reliance on forward-looking statements signifies uncertainty in the company's future performance and plans, which could deter investor confidence.
FAQ
What recent compliance news did Portage Biotech announce?
Portage Biotech announced it received confirmation of compliance with Nasdaq listing requirements on June 24, 2025.
Where is Portage Biotech located?
Portage Biotech is formed under the laws of the British Virgin Islands.
What type of company is Portage Biotech?
Portage Biotech is a clinical-stage immuno-oncology company focused on developing novel biologics for cancer treatment.
How can I find more information about Portage Biotech?
For more information, visit Portage Biotech's official website at www.portagebiotech.com.
What should investors know about forward-looking statements?
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.
About Portage Biotech
Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system’s ability to fight cancer. For more information, visit
www.portagebiotech.com
.
Forward-Looking Statements
All statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company’s business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words “believe,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “plans,” “potential,” “continues,” or similar expressions or variations on such expressions are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not secure financing, the uncertainty of the Company’s ability to continue as a going concern, scientific results may not be as expected, and other factors set forth in “Item 3 - Key Information-Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2024 and “Business Environment – Risk Factors” in the Company’s Management’s Discussion and Analysis for the Three and Six Months ended September 30, 2024, filed as Exhibit 99.2 to the Company’s Form 6-K. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
For More Information:
Portage Biotech
Alexander Pickett, Chief Executive Officer
[email protected]
